首页> 美国卫生研究院文献>BMJ Open >Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis
【2h】

Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis

机译:新一代抗抑郁药对儿童和青少年重大抑郁症的比较疗效和耐受性:单个患者数据荟萃分析的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionAlthough previous conventional meta-analyses and network meta-analyses have provided some important findings about pharmacological treatments for children and adolescents with depressive disorders in the past decades, several questions still remain unsolved by the aggregate data from those meta-analyses. Individual participant data meta-analysis (IPD-MA) enables exploration of the impacts of individual characteristics on treatment effects, allowing matching of treatments to specific subgroups of patients. We will perform an IPD-MA to assess the efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents.
机译:引言尽管在过去的几十年中,以前的常规荟萃分析和网络荟萃分析提供了一些有关抑郁症儿童和青少年药物治疗的重要发现,但这些荟萃分析的汇总数据仍未解决一些问题。个体参与者数据荟萃分析(IPD-MA)使您能够探索个体特征对治疗效果的影响,从而使治疗与患者的特定亚组相匹配。我们将执行IPD-MA评估新一代抗抑郁药对儿童和青少年重大抑郁症的疗效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号